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LETTER TO THE EDITOR
Small airway function in Finnish COVID-19 
survivors
Anna Lindahl1,2* , Jere Reijula3, Leo Pekka Malmberg4, Miia Aro2, Tuula Vasankari2,5 and Mika Juhani Mäkelä4 
Abstract 
Follow-up studies of COVID-19 patients have found lung function impairment up to six months after initial infection, 
but small airway function has not previously been studied. Patients (n = 20) hospitalised for a severe SARS-CoV-2 
infection underwent spirometry, impulse oscillometry, and multiple measurements of alveolar nitric oxide three to six 
months after acute infection. None of the patients had small airway obstruction, nor increased nitric oxide concentra-
tion in the alveolar level. None of the patients had a reduced  FEV1/FVC or significant bronchodilator responses in IOS 
or spirometry. In conclusion, we found no evidence of inflammation or dysfunction in the small airways.
Keywords: COVID-19, Small airways, Airway inflammation, Viral infection, Nitric oxide, Impulse oscillometry
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
There is some knowledge already emerging on the effects 
of Coronavirus Disease 2019 (COVID-19) on lung func-
tion. Lung function impairment has been described up 
to six months after acute infection [1, 2]. To date, these 
studies have indicated that COVID-19 infection affects 
mostly lung volume and diffusing capacity. In addition, 
follow-up studies of the previous coronavirus diseases 
Severe Acute Respiratory Syndrome (SARS) and Middle 
East Respiratory Syndrome (MERS) have shown persist-
ing pulmonary impairment, including ventilation restric-
tion and impaired diffusing capacity, as well as lung 
fibrosis and other radiological abnormalities, persist-
ing in up to 15 years follow-up [3, 4]. To our knowledge, 
small airway function measurements, such as impulse 
oscillometry (IOS) or extended exhaled nitric oxide 
(NO) measurements, have not previously been studied in 
SARS, MERS, or COVID-19 patients.
Methods
Patients hospitalised due to a documented COVID-19 
in the Helsinki metropolitan area, covered by Helsinki 
University Hospital in Finland, underwent lung function 
tests three to six months after hospital discharge. The 
inclusion criteria were (a) the patient had been admitted 
to the intensive care unit (ICU) or (b) the cohort ward 
clinician had classified the patient’s disease as “severe”. 
Twenty-seven patients were randomly selected, accord-
ing to the capacity of the routine clinical physiology 
lab’s resources, to undergo IOS and multiple flow meas-
urements of exhaled NO in addition to spirometry and 
diffusing capacity test. Five patients later declined to par-
ticipate or did not give written consent, and two patients 
were later excluded for use of inhaled long-acting beta 
agonist therapy. The study was approved by the Research 
Ethics Committee of Helsinki University Hospital (§148 
HUS/1922/2020).
IOS and spirometry manoeuvres were measured in 
this particular order, and triplicate measurements were 
recorded in line with ATS/ERS guidelines using Vyntus 
Pneumo/IOS (Vyaire Medical, Hoechberg, Germany). 
Participants inhaled 400 μg salbutamol via spacer (Volu-
matic) immediately after the baseline measurements and 
performed postbronchodilator measurements 15  min 
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Table 1 Spirometry, impulse oscillometry and exhaled nitric oxide results
FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEV1/FVC forced expiratory ratio, MMEF maximal mid-expiratory flow, MEF50 maximal flow at 50% of FVC, 
IOS impulse oscillometry, R5 resistance at 5 Hz, R5-20 differential change in airway resistance between 5 and 20 Hz, X5 reactance at 5 Hz, AX area of reactance, NO nitric 
oxide, FENO fractional concentration of NO with flow 50 ml/s, NOalv alveolar NO concentration
Pre-bronchodilator Post-bronchodilator Change
Abs Z Abs Z %
Spirometry
 FVC, l
  Mean ± SD 4.53 ± 0.96 − 0.18 ± 0.88 4.45 ± 1.01 − 0.30 ± 0.96 − 1.8 ± 2.3
  Median (IQR) 4.47 (3.99–4.88) − 0.10 (− 0.87–0.24) 4.28 (3.87–5.02) − 0.13 (− 1.09–0.28) − 2.4 (− 3.5–0.0)
  Range 2.45–6.46 − 1.28–1.65 2.39–6.54 − 1.67–1.78 − 5.3–2.9
  FEV1, l
  Mean ± SD 3.59 ± 0.71 0.09 ± 0.91 3.65 ± 0.74 0.21 ± 0.94 1.7 ± 1.9
  Median (IQR) 3.55 (3.23–3.99) 0.23 (− 0.59–0.73) 3.63 (3.21–4.15) 0.31 (− 0.44–0.92) 2.2 (− 0.3–3.3)
  Range 1.96–5.28 − 1.66–2.15 1.97–5.37 − 1.62–2.31 − 2.5–4.7
  FEV1/FVC, %
  Mean ± SD 79.57 ± 4.24 0.57 ± 0.99 82.45 ± 4.89 1.11 ± 1.06 3.6 ± 2.1
  Median (IQR) 81.55 (75.78–82.72) 0.89 (− 0.43–1.39) 82.34 (79.25–85.97) 0.91 (− 0.07–2.15) 3.2 (2.1–5.8)
  Range 68.88–84.62 − 0.93–1.75 71.10–90.53 − 0.52–2.62 − 0.1–7.0
 MMEF, l·s−1
  Mean ± SD 3.49 ± 0.95 0.49 ± 1.13 3.95 ± 1.03 1.02 ± 1.23 13.6 ± 6.6
  Median (IQR) 3.49 (2.68–4.09) 0.59 (− 0.41–1.06) 3.99 (3.04–4.77) 0.94 (− 0.07–1.79) 13.4 (9.3–16.0)
  Range 1.87–5.57 − 1.48–2.81 2.07–6.06 − 0.95–3.32 − 0.9–26.7
  MEF50, l·s−1
  Mean ± SD 4.23 ± 1.10 0.44 ± 1.04 4.83 ± 1.07 0.99 ± 0.97 15.9 ± 14.3
  Median (IQR) 4.02 (3.46–4.91) 0.61 (− 0.21–1.00) 4.78 (3.98–5.63) 1.25 (0.37–1.42) 13.2 (7.5–19.0)
  Range 2.21–6.54 − 1.28–2.45 2.78–7.03 − 0.76–2.86 − 10.4–49.9
IOS
 R5, kPa·l−1·s
  Mean ± SD 0.30 ± 0.09 − 0.06 ± 1.00 0.27 ± 0.07 − 0.60 ± 1.58 − 7 ± 12
  Median (IQR) 0.28 (0.24–0.39) − 0.01 (− 0.51–0.38) 0.27 (0.23–0.32) − 0.29 (− 0.95–0.04) − 8 (− 15–3)
  Range 0.13–0.45 − 1.89–2.49 0.12–0.39 − 5.78–1.98 − 23–18
 R5-20, kPa·l−1·s
  Mean ± SD 0.03 ± 0.03 − 0.98 ± 0.98 0.03 ± 0.02 − 1.04 ± 1.55 13 ± 73
  Median (IQR) 0.04 (0.01–0.05) − 0.79 (− 1.55 to − 0.45) 0.02 (0.01–0.06) − 0.86 (− 1.73 to − 0.42) − 10 (− 42–60)
  Range − 0.02–0.09 − 2.94–1.11 − 0.02–0.06 − 4.41–3.58 − 95–179
 X5, kPa·l−1·s
  Mean ± SD − 0.08 ± 0.03 1.07 ± 1.39 − 0.07 ± 0.03 1.69 ± 2.00 − 16 ± 21
  Median (IQR) − 0.08 (− 0.09 to − 0.06) 0.76 (0.05–1.81) − 0.07 (− 0.08 to − 0.05) 1.08 (0.54–2.19) − 16 (− 31–1)
  Range − 0.14 to − 0.03 − 0.74–5.05 − 0.13 to − 0.01 − 0.99–7.10 − 59–21
 AX, kPa·L−1
  Mean ± SD 0.27 ± 0.19 − 0.32 ± 0.66 0.19 ± 0.13 − 0.10 ± 1.52 − 22 ± 30
  Median (IQR) 0.29 (0.10–0.41) − 0.18 (− 0.60–0.11) 0.18 (0.08–0.29) − 0.37 (− 0.63 to − 0.19) − 26 (− 46 to − 6)
  Range 0.04–0.72 − 2.46–0.67 0.01–0.46 − 1.22–6.13 − 75–53
Exhaled NO
  FENO, ppb
  Mean ± SD 21.7 ± 6.9 N/A N/A N/A N/A
  Median (IQR) 21.8 (17.0–28.2) N/A N/A N/A N/A
  Range 9.1–31.2 N/A N/A N/A N/A
  NOalv, ppb
  Mean ± SD 1.4 ± 1.0 − 1.19 ± 0.58 N/A N/A N/A
  Median (IQR) 1.4 (0.6–1.7) − 1.20 (− 1.69 to − 1.02) N/A N/A N/A
  Range 0.2–3.9 − 1.93–0.30 N/A N/A N/A
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later. Spirometry variables evaluated were forced vital 
capacity (FVC), forced expiratory volume in one second 
 (FEV1), forced expiratory ratio  (FEV1/FVC), maximal 
mid-expiratory flow (MMEF), and maximal flow at 50% 
of FVC  (MEF50). IOS variables evaluated were resistance 
at 5  Hz (R5), the frequency dependence of resistance 
in terms of the difference between R5 and resistance at 
20 Hz (R5-20), reactance at 5 Hz (X5), and area of reac-
tance (AX).
Multiple flow measurements of exhaled NO (30, 50, 
100 and 200 ml/s) were evaluated with a chemilumines-
cence analyser (CLD 77, EcoPhysics, Duernten, Switzer-
land) to obtain the fractional concentration of NO with 
flow 50 ml/s  (FENO), and the alveolar NO concentration 
 (NOalv) by using the extended analysis [5].
The lung function results were compared with the 
healthy reference values of the same gender, age and/or 
height and expressed as Z-scores [6–9].
Results
The mean age of participants (14/20 male) was 56 (range 
34–72), and the mean BMI was 29.6. Ten patients (50%) 
had one or more comorbidities, the two most common 
being hypertension (30%) and type 2 diabetes (25%). One 
patient had asthma but did not use any inhaled asthma 
medications. Other pulmonary diseases were not present 
in the study population. There were no current smok-
ers in the study population, while six participants (30%) 
reported former smoking, 13 (70%) were never-smokers, 
and one gave no answer.
The mean duration of hospital treatment was 19 days. 
Ten (50%) were admitted to ICU and eight (40%) needed 
mechanical ventilation. The mean duration of intensive 
care was 17  days and mechanical ventilation 16  days, 
respectively. Of the 12 participants who were not intu-
bated, 10 (91%) needed supplementary oxygen therapy, 
with the mean peak flow rate of 10  l/min. Three (15%) 
had a pulmonary embolism during initial hospitalisation 
or during the recovery.
IOS, spirometry, and exhaled NO measurements were 
performed by 20 (100%), 19 (95%), and 18 (90%) partici-
pants, respectively. On average, the lung function tests 
were performed 154  days (5.1  months) after symptom 
onset. The results are presented in Table 1 and summa-
rised in Fig. 1.
There was no evidence of small airway obstruction in 
IOS in any of the 22 participants, as expressed by the 
frequency dependence of resistance (R5-20) or the reac-
tance area (AX), which are putative markers of small 
20 adult patients hospitalised
due to severe COVID-19,








FVC, FEV1/FVC, MEF50, MMEF
normal in all patients
No significant bronchodilator
responses
Mildly reduced FEV1 (Z-score
-1.66, 81% predicted value) in one
patient
No sign of small airway
obstruction in AX or R5-20
No significant bronchodilator
responses
Slightly elevated FENO (25-50
ppb) in seven (39%)
None had FENO >50 ppb
NOalv normal in all patients
Fig. 1 Flowchart of small airway function at 3–6 months follow-up in 20 adult patients hospitalised due to COVID-19. AX area of reactance, R5-20 
differential change in airway resistance between 5 and 20 Hz, FVC forced vital capacity, FEV1/FVC forced expiratory ratio, MEF50 maximal flow at 
50% of FVC, MMEF maximal mid-expiratory flow, FEV1 forced expiratory volume in 1 s, FENO fractional concentration of nitric oxide with flow 50 ml/s, 
NOalv alveolar nitric oxide concentration
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airway function [10]. One patient had a mildly reduced 
 FEV1 (z = − 1.66, 81% of predicted). The patients had nei-
ther a lowered  FEV1/FVC, MMEF,  MEF50, nor a signifi-
cant bronchodilator response in spirometry or in IOS (R5 
reduction > 40%).
Seven patients (39%) had slightly elevated  FENO of 25 
to 50 ppb, indicating possible inflammation. None of the 
participants had an abnormal  FENO of more than 50 ppb. 
In addition,  NOalv, indicating the NO production in the 
small airways, was low or in the normal range in all par-
ticipants (Table 1).
Discussion
Our study indicates that even among patients with very 
severe COVID-19 infection, the bronchial inflammation 
distally in the small airways is not present three to six 
months after original infection, and there were neither 
long-term impairments in small airway function, nor 
new asthma cases. This could imply that COVID-19 does 
not induce chronic bronchial inflammation or predispose 
to chronic obstructive diseases.
One should note that our sample size was small due to 
the clinical physiology lab’s limited resources amidst the 
pandemic, and our study lacked a control group. How-
ever, the assessment of small airway indices was based on 
previously published reference values matched with the 
present study sample. Moreover, the participants in our 
study had recovered from a considerably severe COVID-
19, with half of the patients (10/20) admitted to ICU 
and almost half (8/20) needing mechanical ventilation 
due to COVID-19. Thus, our results cannot be directly 
generalised to patients with a milder disease, although 
the severity of lung function impairment has previously 
been associated with the severity of the initial infection 
[1], suggesting that patients with a less severe COVID-19 
might have even fewer abnormal findings in small airway 
function.
In conclusion, small airways do not seem to be affected 
in COVID-19 survivors at three to six months after 
the initial infection. Therefore, future follow-up stud-
ies should focus on the effects of COVID-19 on diffus-
ing capacity and lung volumes, as evidence suggests that 
COVID-19 causes damage rather to the lung parenchyma 
and microcirculation than on the bronchial level.
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